Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (102731)	9/22/2022 8:26:11 AM
From: Goose94	Read Replies (1) \| Respond to of 203018

Blackhawk Growth (BLR-Cse) Mindbio Nominated for Company of the Year by Industry Peers as it Prepares for Phase 2 Clinical Trials Sept 22, '22 - NR Blackhawk Growth is pleased to report that its subsidiary, MindBio Therapeutics (“MindBio”), and its Co-Founder Justin Hanka, have been nominated for a number of annual awards by global industry peers in the annual Microdose Awards. Investors can vote for MindBio and Co-Founder Justin Hanka here MindBio has been nominated in the category of Company of the Year alongside industry leaders Cybin, Dr. Bronner’s, Microdose Therapeutics and Psilera. MindBio is also nominated in the category for LSD Company of the Year alongside Beckley Psytech, BetterLife Pharma, MindMed and Psygen. MindBio’s Co-Founder Justin Hanka has been nominated for Entrepreneur of the Year alongside industry leaders Christian Angermayer, David Champion, Iri Selkirk and Chris Witowski. Mr Hanka has also been nominated in the category of Innovator of the Year alongside industry leaders Najla Guthrie, Dr. Darryl Hudson, Lars Christian Wilde and Jacki Von Salm. The awards will be presented at the upcoming Wonderland Convention in Miami in November. MindBio is also pleased to announce that preparations are well underway for the start of their Phase 2 Clinical trials and further announcements will be made after the presentation and reveal of data from their Phase 1 LSD Microdosing Clinical Trials in 80 healthy subjects. “MindBio is leading the way in psychedelic microdosing clinical trials. With the recent successful completion of MindBio’s Phase 1 clinical trial, the MindBio team is now preparing for Phase 2 Clinical Trials and progressing its work with a strong focus towards commercialization,” said Frederick Pels, CEO of Blackhawk. About Blackhawk Growth Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. For further information please contact: Frederick Pels, Chief Executive Officer (403)-991-7737 fred@blackhawkgrowth.com